---
document_datetime: 2026-02-10 14:01:28
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/elucirem-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: elucirem-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.1316131
conversion_datetime: 2026-02-13 18:54:14.074553
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.2
  docling: 2.73.1
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Elucirem

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number         | Scope   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary     |
|----------------------------|---------|-------------------------------------|---------------------------------------------|----------------------------------|-------------|
| PSUR / EMA/PSUR/0000296586 |         |                                     |                                             |                                  | Maintenance |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000262375   | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 27/03/2025   |            |             |                                                                               |
|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000249008   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.6 Change(s) to therapeutic indication(s) - C.I.6.a Addition of a new therapeutic indication or modification of an approved one - Accepted Extension of indication to include treatment of new population (0 to 2 years of age patients) for Elucirem / Vueway, based on final results from study GDX-44-015; this is a phase ii clinical study concerning gadopiclenol pharmacokinetics, safety and efficacy in pediatric patients < 2 years of age undergoing contrast-enhanced MRI; extension of indication is also supported with the non-clinical data. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 0.4 of the RMP has also been submitted. As | 11/12/2025   | 22/01/2026 | SmPC and PL | Please refer to Scientific Discussion 'Elucirem/Vueway - II- EMAVR0000289008' |

<div style=\"page-break-after: always\"></div>

| Article 61(3) / EMA/N/0000309692      | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with the addition of contact details of local representatives.                                                                                                                                                                                                                                                                         | 14/11/2025   | 22/01/2026   | PL   |                   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------|-------------------|
| Variation type II /                   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.b Substantial change to the manufacturing process of the active substance which may have a significant impact on the quality, safety or efficacy of the medicinal product - Accepted | 04/09/2025   |              |      | EMA/VR/0000253566 |
| Variation type IB / EMA/VR/0000295104 | B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted                                                                                                                                                                                    | 24/09/2025   |              |      |                   |
| Variation type IA /                   | B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where                                                                                                                                                                                                                                                  | 26/02/2025   |              |      | EMA/VR/0000255142 |

<div style=\"page-break-after: always\"></div>

|                     | batch control/testing takes place - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------------|
| Variation type IA / | This was an application for a group of variations. A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted B.I.a.3 Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.a Up to 10-fold increase compared to the originally approved batch size - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where | 02/02/2026 | EMA/VR/0000323426 |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000268127   | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.z Change in the holding time of an intermediate - Accepted   | 23/07/2025   |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|